Who Exports Repaglinide from India — 41 Suppliers Behind a $6.9M Market
India's repaglinide export market is supplied by 41 active exporters who collectively shipped $6.9M across 819 shipments. AUROBINDO PHARMA LTD leads with a 51.4% market share, followed by AUROBINDO PHARMA LIMITED and USV PRIVATE LIMITED. The top 5 suppliers together control 98.5% of total export value, reflecting a concentrated market structure.
Top Repaglinide Exporters from India — Ranked by Export Value
AUROBINDO PHARMA LTD is the leading repaglinide exporter from India, holding a 51.4% share of the $6.9M market across 819 shipments from 41 exporters. The top 5 suppliers — AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, USV PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED, MACLEODS PHARMACEUTICALS LTD — collectively control 98.5% of total export value, indicating a highly concentrated market. Individual shares are: AUROBINDO PHARMA LTD (51.4%), AUROBINDO PHARMA LIMITED (25.5%), USV PRIVATE LIMITED (12.8%), INTAS PHARMACEUTICALS LIMITED (5.0%), MACLEODS PHARMACEUTICALS LTD (3.9%).
Top Repaglinide Exporters from India
Ranked by export value · 41 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD REPAGLINIDE TABLETS 1 MG 100'SREPAGLINIDE TABLETS 2 MG REPAGLINIDE TABLETS USP 2 MG 100'SREPAGLINIDE TABLETS 2 MG 100'S | $3.6M | 6 | 51.4% |
| 2 | AUROBINDO PHARMA LIMITED REPAGLINIDE TABLETS 1 MG 100'SREPAGLINIDE TABLETS 2 MG REPAGLINIDE TABLETS USP 2 MG 100'SREPAGLINIDE TABLETS 2 MG 100'S | $1.8M | 6 | 25.5% |
| 3 | USV PRIVATE LIMITED REPAGLINIDE TABLETS 1 MG(REPAGLINIDE ARRREPAGLINIDE MYLAN PH. 2MGTAB 15'S(6X15'SREPAGLINIDE TABLET 2MG 3X10 S VN | $883.7K | 4 | 12.8% |
| 4 | INTAS PHARMACEUTICALS LIMITED PH.DRU.& MED.: VATINID 2MG TABLETS [11697 PACK X9X10T]PHARMA DRUGS & MEDI REPAGLINIDE ACCORD 1PHARMA DRUGS & MEDI REPAGLINIDE ACCORD 2 | $343.0K | 6 | 5.0% |
| 5 | MACLEODS PHARMACEUTICALS LTD REPAGLINIDE TABLETS 1 MG 100'SREPAGLINIDE TABLETS 2 MG REPAGLINIDE TABLETS USP 2 MG 100'SREPAGLINIDE TABLETS 2 MG 100'S | $267.7K | 1 | 3.9% |
| 6 | GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED | $48.3K | 2 | 0.7% |
| 7 | INTAS PHARMACEUTICALS LTD PH.DRU.& MED.: VATINID 2MG TABLETS [11697 PACK X9X10T]PHARMA DRUGS & MEDI REPAGLINIDE ACCORD 1PHARMA DRUGS & MEDI REPAGLINIDE ACCORD 2 | $22.0K | 3 | 0.3% |
| 8 | ANR HEALTH CARE PRIVATE LIMITED | $6.9K | 1 | 0.1% |
| 9 | M T MADON EXPORTS REPAGLINIDE TABLETS 1 MG 100'SREPAGLINIDE TABLETS 2 MG REPAGLINIDE TABLETS USP 2 MG 100'SREPAGLINIDE TABLETS 2 MG 100'S | $1.7K | 1 | 0.0% |
| 10 | GMSANJIVANI LLP | $1.7K | 2 | 0.0% |
| 11 | DOSHI MEDICARE PRIVATE LIMITED | $1.6K | 1 | 0.0% |
| 12 | DOLPHIN PHARMACEUTICAL | $1.4K | 1 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Repaglinide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes (March 2024) | Yes | 89 | WHO GMP compliance accepted for Unit IV in March 2024. |
| Intas Pharmaceuticals Limited | Approved | Yes (April 2007) | Yes | 89 | First Indian company to receive EU GMP certification in April 2007. |
| Macleods Pharmaceuticals Ltd | Approved | Yes | Yes | Not specified | Holds US DMF for Prasugrel Hydrochloride. |
TransData Nexus reviewed the regulatory standing of 3 leading Repaglinide exporters from India. 3 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Repaglinide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal center for active pharmaceutical ingredient (API) production. The city contributes approximately 40% of the country's bulk drug output, underscoring its significance in the pharmaceutical supply chain. This prominence is bolstered by the presence of Hyderabad Pharma City, an expansive industrial park dedicated to pharmaceutical manufacturing and research. The park aims to position Hyderabad as a global leader in pharma and biotech innovation, fostering a sustainable and eco-friendly environment that aligns with global standards.
Notably, Aurobindo Pharma Limited, headquartered in Hyderabad, is a major exporter of Repaglinide, accounting for 51.4% of total exports valued at $3.6 million. The company's strategic location within this cluster facilitates efficient production and distribution of APIs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat leads India with a 33% share in drug manufacturing and a 28% share in drug exports. The region hosts numerous USFDA-certified manufacturing facilities, reflecting its adherence to international quality standards.
Companies like Intas Pharmaceuticals Limited, based in Ahmedabad, contribute significantly to the export of Repaglinide, holding a 5.0% share valued at $0.3 million. The cluster's emphasis on formulations ensures a steady supply of finished pharmaceutical products to global markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a crucial export gateway for India's pharmaceutical industry. Its strategic coastal location and well-developed infrastructure facilitate seamless international trade. Pharmaceutical companies in this cluster benefit from proximity to major ports, enhancing their export capabilities.
While specific data on Repaglinide exports from this region is limited, the cluster's role as an export hub underscores its importance in the global pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies, leading to substantial growth in production capacities.
Although the region's contribution to Repaglinide exports is not explicitly detailed, its overall impact on India's pharmaceutical output is noteworthy.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with over-reliance on a single supplier, consider engaging with multiple manufacturers across different clusters.
- Evaluate Supplier Capabilities: Assess the production capacities and quality standards of potential suppliers, ensuring they meet international regulatory requirements.
- Leverage Regional Strengths: Utilize the specific strengths of each cluster—such as API production in Hyderabad and formulations in Ahmedabad-Vadodara—to optimize the supply chain.
- Monitor Regulatory Compliance: Regularly review suppliers' compliance with regulatory standards to maintain product quality and avoid potential disruptions.
By strategically sourcing from India's diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their supply chains for products like Repaglinide.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Repaglinide exporters from India
Aurobindo Pharma Limited — Aurobindo Pharma acquires Lannett Company for $250 million
Aurobindo Pharma's US subsidiary entered a definitive agreement to acquire Lannett Company LLC, a US-based generic pharmaceuticals manufacturer, for $250 million. This acquisition aims to expand Aurobindo's US manufacturing capacity and portfolio, particularly in ADHD therapies and complex controlled substances. The transaction is subject to US FTC and regulatory approval and is expected to close within 8-12 months. - IMPACT: This acquisition is anticipated to enhance Aurobindo's production capabilities, potentially increasing Repaglinide exports.
Impact: This acquisition is anticipated to enhance Aurobindo's production capabilities, potentially increasing Repaglinide exports.
Aurobindo Pharma Limited — Aurobindo Pharma USA collaborates with global pharma major on respiratory products
Aurobindo Pharma USA Inc., a wholly owned subsidiary of Aurobindo Pharma, entered into a collaboration and license agreement with an unnamed global pharmaceutical company for the development and commercialization of specific products in the respiratory therapeutic area. The agreement spans an initial estimated development duration of three to five years, with both parties co-exclusively commercializing the products. Aurobindo committed to an upfront payment of $25 million and a cost-sharing arrangement capped at $90 million over the development period. - IMPACT: While focused on respiratory products, this collaboration may free up resources within Aurobindo, potentially benefiting Repaglinide production and exports.
Impact: While focused on respiratory products, this collaboration may free up resources within Aurobindo, potentially benefiting Repaglinide production and exports.
Aurobindo Pharma Limited — Aurobindo Pharma acquires Khandelwal Labs' non-oncology prescription business for ₹325 crore
Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd for ₹325 crore. The acquisition includes 23 established brands across 67 stock-keeping units in pain management and anti-infective segments, along with nine pipeline products. This move aims to strengthen Aurobindo's presence in the domestic formulations market. - IMPACT: The acquisition enhances Aurobindo's domestic market presence, potentially leading to increased production capacity and resources that could positively impact Repaglinide exports.
Impact: The acquisition enhances Aurobindo's domestic market presence, potentially leading to increased production capacity and resources that could positively impact Repaglinide exports.
Common Questions — Repaglinide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which repaglinide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AUROBINDO PHARMA LTD leads with 265 recorded shipments worth $3.6M. AUROBINDO PHARMA LIMITED (136 shipments) and USV PRIVATE LIMITED (46 shipments) are also established high-volume exporters.
Q How many repaglinide manufacturers are there in India?
India has 41 active repaglinide exporters with a combined export market of $6.9M across 819 shipments to 36 countries. The top 5 suppliers hold 98.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for repaglinide from India?
Average FOB unit price: $1.54 per unit, ranging from $0.00 to $54.95. Average shipment value: $8.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 41 verified Indian exporters of Repaglinide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 819 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 36 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
819 Verified Shipments
41 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists